As of this afternoon (3:30 p.m. ET), it’s up 13%. Back above $0.10. Which, let’s be honest, isn’t exactly a fortune, but it’s a definite… blip. A flicker of hope in the vast, grey landscape of crypto winter. I’ve been trying to be sensible. To diversify. To invest in things with…utility. But then Dogecoin does this. It’s terribly distracting.
This happened in the last quarter, you see. February the sixth, 2026, to be precise. BlueStem shelled out about $10.6 million – enough to buy a small island, or a truly magnificent collection of rubber ducks. They seem to think these little bond things are worth a nibble, and who are we to argue with people who manage other people’s money? Though, frankly, I suspect they’ve got a secret stash of chocolate biscuits hidden somewhere in the office.
The fourth-quarter earnings report, delivered with the quiet precision of a skilled lepidopterist pinning a specimen, offered a curious reprieve. A modest outperformance on both top and bottom lines, coupled with cautiously optimistic guidance for 2026, seemed to momentarily arrest the downward drift. It was, shall we say, a fleeting glimpse of sunshine through the rather overcast foliage of recent performance.
The company’s quarterly report, delivered this morning, initially presented a façade of prosperity. Earnings and revenue exceeded the expectations of those who attempt to predict the future (a notoriously unreliable endeavor). Yet, within this apparent success lay a foreshadowing of turbulence – a cautionary note regarding the quarters to come. It is as if the company offered a perfect mirror, reflecting not present gains, but future anxieties.
Our former President, never one to be outdone, promptly slapped on a new 15% “global” tariff under something called Section 122 of the Trade Act of 1974. Sounds thrilling, doesn’t it? Like a James Bond film, except with more paperwork and less Sean Connery. As your friendly neighborhood portfolio manager, let me break down what this means for your investments, and frankly, for the sanity of anyone trying to predict the future.
According to a filing with the Securities and Exchange Commission – a body dedicated to ensuring that everyone understands precisely what everyone else is doing with money, which is a noble, if slightly Sisyphean, task – BVF increased its stake in Structure Therapeutics. The increase totaled 275,105 shares, valued at approximately $11.2 million based on the quarterly average share price. At quarter-end, BVF’s total holding in Structure Therapeutics was valued at $242.0 million, an increase of $152.3 million. This figure, naturally, accounts for both actual purchases and the somewhat unpredictable movement of share prices, a phenomenon which often appears to defy the laws of physics.
The valuation is based on the SEC Form 4’s weighted average purchase price of $7.89, a figure that now feels… distant. The post-transaction value reflects the market close on February 20, 2026, also at $7.89 – a coincidence, perhaps, or a premonition of further adjustments.
He wasn’t born to the scent of money, but he learned to read the signs. He understood early on that technology wasn’t about transistors and code, but about leverage – about multiplying effort, and ultimately, about power. Palantir, the data firm he helped birth, was built on that principle. And a man who understands leverage understands risk. He knows when the scales are tipping, when the promises are getting thin.
The SEC filing of February 17th confirms BVF’s complete divestiture from Protagonist Therapeutics. The value of their position, once a rather plump specimen in the portfolio, has evaporated – a diminution of $170.12 million. It’s a figure that hums with a quiet significance, a whispered note in the cacophony of market transactions. One suspects there’s a narrative concealed within the numbers, a story BVF isn’t shouting from the rooftops.
And it is within this breathless pursuit of the next wave that one finds, perhaps surprisingly, a quiet strength in Nokia (NOK +1.14%). A company, often overlooked, yet poised, it seems, to capitalize on the inevitable—the coming of 6G. A gamble, yes, but one rooted in a peculiar, almost melancholic, necessity.